TuHURA Biosciences, Inc./NV
For the period ended Jun 20, 2024. Filed May 17, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 20, 2024 · Filed May 17, 2024
HURA$1.63+1.2%Stored close · as of Nov 6, 2026
Contents
Pay Versus Performance Table
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”) and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive compensation for our principal executive officers (“PEOs”) and non-PEO named executive officers (“NEOs”) and Company performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.
| Year | SummaryCompensationTable Total forMr. Hoffman(1) | SummaryCompensationTable Total forMr. Zarrabian(2) | CompensationActually Paid toMr. Hoffman(4) | CompensationActually Paid toMr. Zarrabian(4) | AverageSummaryCompensationTable Total forNon-PEO NEOs(3) | AverageCompensationActually Paid toNon-PEONEOs(4) | Value ofInitial Fixed$100InvestmentBased OnTotalShareholderReturn(“TSR”)(5) | Net Income(Loss)(millions)(6) |
|---|---|---|---|---|---|---|---|---|
| (a) | (b(1)) | (b(2)) | (c) | (c) | (d) | (e) | (f) | (g) |
| 2023 | 1,184,363 | - | 559,020 | - | 332,173 | 262,974 | 3.82 | (15) |
| 2022 | 3,161,028 | 682,827 | 1,208,847 | (37,000) | 340,655 | (125,878) | 12.09 | (23) |
| (1) | The dollar amounts reported in column (b(1)) are the amounts of total compensation reported for Robert E. Hoffman (our current Chief Executive Officer) for each corresponding year in the “Total” column of the Summary Compensation Table. Refer to “Executive Compensation—Summary Compensation Table.” |
| (2) | The dollar amounts reported in column (b(2)) are the amounts of total compensation reported for Saiid Zarrabian (our former Chief Executive Officer who served in such capacity during the fiscal year ended June 30, 2022 until Mr. Hoffman’s appointment as our Chief Executive Officer, effective November 8, 2021) for the fiscal year ended June 30, 2022 in the “Total” column of the Summary Compensation Table in the Proxy Statement for our 2023 Annual Meeting, filed with the SEC on March 31, 2023. |
| (3) | The dollar amounts reported in column (d) represent the average of the amounts reported for our named executive officers as a group (excluding Mr. Hoffman and Mr. Zarrabian) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding Mr. Hoffman and Mr. Zarrabian) included for purposes of calculating the average amounts in each applicable year are as follows: for 2023, Dennis Brown and Scott Praill, and for 2022, Dennis Brown (our former Chief Scientific Officer), Scott Praill (our former Chief Financial Officer) and John Liatos (our former Senior Vice President of Business Development). |
| (4) | Compensation actually paid to the named executive officers represents the “Total” compensation reported in the Summary Compensation Table for the applicable fiscal year, as adjusted as follows: |
| 2023 | 2022 | |||||
|---|---|---|---|---|---|---|
| Adjustments | Mr. Hoffman ($) | Mr. Zarrabian ($) | Average OtherNEOs ($) | Mr. Hoffman ($) | Mr. Zarrabian ($) | Average OtherNEOs ($) |
| Deduction for amounts reported under the stock awards column in the summary compensation table | (416,383) | - | (92,291) | (2,622,597) | - | - |
| ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End | 356,018 | - | 46,004 | 792,880 | - | - |
| ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date | - | - | - | 28,198 | - | - |
| Increase/deduction for Awards Granted during Prior FY that were Outstanding and Unvested as of Applicable FY End, determined based on change in ASC 718 Fair Value from Prior FY End to Applicable FY End | (355,918) | - | (4,212) | - | - | (268,033) |
| Increase/deduction for Awards Granted during Prior FY that Vested During Applicable FY, determined based on change in ASC 718 Fair Value from Prior FY End to Vesting Date | (209,061) | - | (18,700) | 150,662 | 270,248 | (105,123) |
| Deduction of ASC 718 Fair Value of Awards Granted during Prior FY that were Forfeited during Applicable FY, determined as of Prior FY End | - | - | - | - | (990,075) | (93,377) |
| TOTAL ADJUSTMENTS | (625,343) | - | (69,199) | (1,952,181) | (719,827) | (466,533) |
| (5) | Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the price per share of our common stock at the end and the beginning of the measurement period by the price per share of our common stock at the beginning of the measurement period. |
| (6) | The dollar amounts reported represent the amount of net income (loss) reflected in our consolidated audited financial statements for the applicable year. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.